Stock Research: BioVersys

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

BioVersys

SWX:BIOV CH0210362643
15
  • Value
    24
  • Growth
    31
  • Safety
    Safety
    12
  • Combined
    6
  • Sentiment
    77
  • 360° View
    360° View
    15
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 15 (better than 15% compared with alternatives), overall professional sentiment and financial characteristics for the stock BioVersys are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for BioVersys. The consolidated Sentiment Rank has a good rank of 77, which means that professional investors are more optimistic about the stock than for 77% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 24, which means that the share price of BioVersys is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 31, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 31% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 12 which means that the company has a riskier financing structure than 88% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
SPI
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
24 n/a n/a n/a
Growth
31 n/a n/a n/a
Safety
Safety
12 n/a n/a n/a
Sentiment
77 n/a n/a n/a
360° View
360° View
15 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
89 n/a n/a n/a
Sentiment
77 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
24 n/a n/a n/a
Growth
31 n/a n/a n/a
Safety Safety
12 n/a n/a n/a
Combined
6 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
7 n/a n/a n/a
Price vs. Earnings (P/E)
78 n/a n/a n/a
Price vs. Book (P/B)
25 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
24 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
94 n/a n/a n/a
Profit Growth
16 n/a n/a n/a
Capital Growth
54 n/a n/a n/a
Stock Returns
16 n/a n/a n/a
Growth
31 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
41 n/a n/a n/a
Refinancing
32 n/a n/a n/a
Liquidity
18 n/a n/a n/a
Safety Safety
12 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to BioVersys and broaden your portfolio horizons.

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Laboratorios Farmaceuticos Rovi

MCE:ROVI
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

DKSH

SWX:DKSH
Country: Switzerland
Industry: Trading & Distribution
Size: Large
Full Stock Analysis

Frequently Asked
Questions

Only the professional market sentiment is positive. The stock is expensive, has low growth, and low financial safety. This is a weak investment proposition. Only a small, highly-speculative investment may be justified by investors who strongly believe the positive sentiment points to an positive future.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: